| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-09-29 | 2030-03 | 2028-03 |
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | RECRUITING | PHASE3 | 2025-09-16 | 2031-01-23 | 2027-10-07 |
| NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | RECRUITING | PHASE3 | 2025-08-22 | 2030-09 | 2027-09 |
| NCT06909214 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | RECRUITING | PHASE4 | 2025-04-17 | 2027-05 | 2026-08 |
| NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | RECRUITING | PHASE1 | 2025-04-11 | 2026-01-06 | 2026-01-06 |
| NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | RECRUITING | PHASE3 | 2025-01-15 | 2028-07 | 2027-07 |
| NCT06799416 | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | COMPLETED | PHASE1 | 2025-01-14 | 2025-08-08 | 2025-08-08 |
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | RECRUITING | PHASE3 | 2024-12-18 | 2029-12 | 2026-09 |
| NCT06637072 | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC | RECRUITING | PHASE4 | 2024-12-10 | 2026-02 | 2026-02 |
| NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | RECRUITING | PHASE2 | 2024-11-11 | 2027-06-14 | 2026-08-17 |
| NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | PHASE2 | 2024-10-23 | 2027-07 | 2027-07 |
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia | RECRUITING | PHASE3 | 2024-10-18 | 2028-06 | 2028-06 |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-09-24 | 2025-11-25 | 2025-11-25 |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | RECRUITING | PHASE3 | 2024-09-18 | 2027-12 | 2025-12 |
| NCT06503731 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) | RECRUITING | PHASE2 | 2024-08-30 | 2027-09 | 2027-09 |
| NCT06284954 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-08-20 | 2026-11 | 2026-11 |
| NCT06392386 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | RECRUITING | PHASE2, PHASE3 | 2024-06-28 | 2026-09-30 | 2026-09-30 |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-04-16 | 2027-07-23 | 2025-07-25 |
| NCT06307626 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. | RECRUITING | PHASE3 | 2024-03-28 | 2027-09 | 2026-09 |
| NCT06307613 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease | RECRUITING | PHASE3 | 2024-03-27 | 2027-09 | 2026-09 |
| NCT05907096 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-02-17 | 2026-07-31 | 2025-11 |
| NCT05979441 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | ENROLLING_BY_INVITATION | PHASE3 | 2023-09-12 | 2027-09 | 2027-09 |
| NCT06203457 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome | COMPLETED | PHASE2 | 2023-08-15 | 2025-02-03 | 2025-02-03 |
| NCT05927415 | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod | COMPLETED | PHASE1 | 2023-07-17 | 2024-06-12 | 2024-06-12 |
| NCT05918978 | Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS | TERMINATED | PHASE2 | 2023-06-20 | 2024-08-15 | 2024-08-15 |
| NCT05817669 | A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) | COMPLETED | PHASE2 | 2023-04-04 | 2024-02-12 | 2024-01-29 |
| NCT05681481 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | TERMINATED | PHASE3 | 2023-03-22 | 2025-03-20 | 2025-03-20 |
| NCT05817435 | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults | COMPLETED | PHASE1 | 2023-03-13 | 2023-05-12 | 2023-05-12 |
| NCT05810948 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-02-21 | 2025-09 | 2025-07-02 |
| NCT05670704 | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants | COMPLETED | PHASE1 | 2023-02-21 | 2024-08-08 | 2024-08-08 |
| NCT05810961 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) | TERMINATED | PHASE2 | 2023-02-20 | 2024-08-05 | 2024-08-05 |
| NCT05405361 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-01-18 | 2029-09-30 | 2029-09-30 |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2022-10-12 | 2027-02-01 | 2026-12-01 |
| NCT05633407 | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | COMPLETED | PHASE2 | 2022-09-23 | 2024-04-18 | 2024-04-18 |
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | PHASE2, PHASE3 | 2022-08-18 | 2028-09 | 2028-09 |
| NCT05267600 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid | COMPLETED | PHASE2, PHASE3 | 2022-06-09 | 2024-09-13 | 2024-09-13 |
| NCT05225675 | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy | COMPLETED | PHASE2 | 2022-03-31 | 2024-06-04 | 2024-06-04 |
| NCT04980495 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-12-16 | 2026-05 | 2023-08-24 |
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-11-17 | 2026-10-01 | 2026-10-01 |
| NCT05163834 | Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV | COMPLETED | PHASE1 | 2021-11-17 | 2022-03-08 | 2022-03-08 |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | RECRUITING | PHASE2, PHASE3 | 2021-10-26 | 2027-03 | 2027-03 |
| NCT04598477 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | TERMINATED | PHASE3 | 2021-07-15 | 2024-03-25 | 2024-03-25 |
| NCT04818671 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients with Generalized Myasthenia Gravis | COMPLETED | PHASE3 | 2021-04-26 | 2024-12-31 | 2024-12-31 |
| NCT04735432 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis | COMPLETED | PHASE3 | 2021-02-05 | 2021-12-13 | 2021-11-02 |
| NCT04687072 | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | COMPLETED | PHASE3 | 2020-12-16 | 2023-10-09 | 2023-10-09 |
| NCT04598451 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | COMPLETED | PHASE3 | 2020-12-01 | 2023-08-22 | 2023-08-22 |
| NCT04280718 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-09-18 | 2027-04-30 | 2027-04-30 |
| NCT04564066 | A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers | COMPLETED | PHASE1 | 2020-08-18 | 2021-02-11 | 2020-12-24 |
| NCT04532125 | SAD and MAD Study With IV and SC Doses of ARGX-117 | COMPLETED | PHASE1 | 2020-08-03 | 2022-08-26 | 2022-08-26 |
| NCT04274452 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) | WITHDRAWN | PHASE3 | 2020-06-29 | 2021-09-01 | 2021-09-01 |
| NCT04225156 | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-06-02 | 2026-03-11 | 2026-03-11 |
| NCT04281472 | A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | COMPLETED | PHASE2 | 2020-04-15 | 2023-05-11 | 2023-05-11 |
| NCT04188379 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | COMPLETED | PHASE3 | 2019-12-16 | 2022-02-03 | 2022-02-03 |
| NCT04073589 | Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects | COMPLETED | PHASE1 | 2019-07-17 | 2019-09-26 | 2019-09-26 |
| NCT03770403 | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. | COMPLETED | PHASE3 | 2019-03-01 | 2022-06-30 | 2022-06-23 |
| NCT03669588 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | COMPLETED | PHASE3 | 2018-08-22 | 2020-04-06 | 2020-04-06 |
| NCT03334058 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus | COMPLETED | PHASE2 | 2017-10-18 | 2020-10-28 | 2020-10-28 |
| NCT03334084 | A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects | COMPLETED | PHASE1 | 2017-10-11 | 2018-09-19 | 2018-09-19 |
| NCT03102593 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP | COMPLETED | PHASE2 | 2017-03-13 | 2019-04-09 | 2019-04-09 |
| NCT02965573 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | COMPLETED | PHASE2 | 2016-12-30 | 2017-10-20 | 2017-10-20 |
| NCT03457649 | IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers | COMPLETED | PHASE1 | 2015-09-09 | 2017-02-21 | 2016-11-15 |
| NCT02759250 | A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | COMPLETED | PHASE1 | 2015-02 | 2018-06 | 2018-04-25 |
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | COMPLETED | PHASE1 | 2014-01 | 2017-03 | 2017-03 |